Candesartan, an angiotensin II at 1-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice

Neuropsychopharmacology

Volumn 37, Issue 13, 2012, Pages 2817-2829

  Villapol, Sonia ^a   Yaszemski, Alexandra K ^a   Logan, Trevor T ^a   Sánchez Lemus, Enrique ^b   Saavedra, Juan M ^b   Symes, Aviva J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

candesartan; inflammation; neuroprotection; PPAR ; TGF ; traumatic brain injury

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; CELL ACTIVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; LEARNING; MALE; MAZE TEST; MICROGLIA; MOTOR PERFORMANCE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRAUMATIC BRAIN INJURY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BRAIN INJURIES; INFUSION PUMPS, IMPLANTABLE; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MOTOR SKILLS; PPAR GAMMA; RANDOM ALLOCATION; TETRAZOLES;

EID: 84869090003     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.152     Document Type: Article

References (82)

1. An J, Nakajima T, Kuba K, Kimura A (2010). Losartan inhibits LPS-induced inflammatory signaling through a PPARgammadependent mechanism in human THP-1 macrophages. Hypertens Res Off J Jap Soc Hypertens 33: 831-835.
2. Ando H, Jezova M, Zhou J, Saavedra JM (2004a). Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann N Y Acad Sci 1018: 345-350.
3. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM (2004b). Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 35: 1726-1731.
4. Ariza M, Matarin MD, Junque C, Mataro M, Clemente I, Moral P et al (2006). Influence of Angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J Neuropsychiatry Clin Neurosci 18: 39-44.
5. Awad AS (2011). Effect of combined treatment with curcumin and candesartan on ischemic brain damage in mice. J Stroke Cerebrovasc Dis 20: 541-548.
6. Baranov D, Armstead WM (2003). Selective blockade of AT1 receptor attenuates impairment of hypotensive autoregulation and improves cerebral blood flow after brain injury in the newborn pig. Anesthesiology 99: 1118-1124.
7. Barkhoudarian G, Hovda DA, Giza CC (2011). The molecular pathophysiology of concussive brain injury. Clin Sports Med 30: 33-48 vii-iii.
8. Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J et al (2011). Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36: 857-870.
9. Benigni A, Cassis P, Remuzzi G (2010). Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2: 247-257.
10. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 43: 993-1002.
11. Bernardo A, Minghetti L (2006). PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12: 93-109.
12. Burson JM, Aguilera G, Gross KW, Sigmund CD (1994). Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 267: E260-267.
13. Chodobski A, Chung I, Kozniewska E, Ivanenko T, Chang W, Harrington JF et al (2003). Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience 122: 853-867.
14. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011). Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26: 699-708.
15. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD (2000). Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 106: 103-106.
16. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G et al (2004). The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24: 467-474.
17. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S et al (2006). Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45: 154-162.
18. Fogari R, Zoppi A (2004). Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 21: 377-393.
19. Gillespie W, Tyagi N, Tyagi SC (2011). Role of PPARgamma, a nuclear hormone receptor in neuroprotection. Indian J Biochem Biophys 48: 73-81.
20. Guan W, Kozak A, El-Remessy AB, Johnson MH, Pillai BA, Fagan SC (2011). Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion. Transl Stroke Res 2: 179-185.
21. Hamm RJ (2001). Neurobehavioral assessment of outcome following traumatic brain injury in rats: an evaluation of selected measures. J Neurotrauma 18: 1207-1216.
22. Hansson L, Lithell H, Skoog I, Baro F, Banki CM, Breteler M et al (1999). Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 8: 177-183.
23. Harasawa S, Otsuka Y, Okubo K, Koike M, Fujita H, Kushiro T et al (2010). Amlodipine suppressed cardiac gene expression of brain natriuretic peptide, transforming growth factor-beta and fibronectin mediated by aldosterone in male strokeprone spontaneously hypertensive rats. J Pharm Pharmacol 62: 1740-1745.
24. Igase M, Kohara K, Miki T (2012). The Association between Hypertension and Dementia in the Elderly. Int J Hypertens 2012: 320648.
25. Ito T, Nishimura Y, Saavedra J (2001). Pre-treatment with candesartan protects from cerebral ischaemia. J Renin Angiotensin Aldosterone Syst 2: 174-179.
26. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM (2002). Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 33: 2297-2303.
27. Ji Y, Liu J, Wang Z, Liu N, Gou W (2009). PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest J Tech Methods Pathol 89: 887-902.
28. Jiao B, Wang YS, Cheng YN, Gao JJ, Zhang QZ (2011). Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-beta1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels. Biosci Trends 5: 173-181.
29. Johren O, Saavedra JM (1996). Expression of AT1A and AT1B angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats. Am J Physiol 271: E104-112.
30. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH et al (2007). Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 322: 1051-1058.
31. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H et al (2010). Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res 1340: 70-80.
32. Lanz TV, Ding Z, Ho PP, Lou J, Agrawal AN, Srinagesh H et al (2010). Angiotensin II sustains brain inflammation in mice via TGF-b. J Clin Invest 120: 2782-2794.
33. Larrayoz IM, Pang T, Benicky J, Pavel J, Sanchez-Lemus E, Saavedra JM (2009). Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 27: 2365-2376.
34. Li JM, Mogi M, Iwanami J, Min LJ, Tsukuda K, Sakata A et al (2008). Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 39: 2029-2036.
35. Liu H, Kitazato KT, Uno M, Yagi K, Kanematsu Y, Tamura T et al (2008). Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. J Hypertens 26: 1435-1445.
36. Loane DJ, Faden AI (2010). Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 31: 596-604.
37. Maeda A, Okazaki T, Inoue M, Kitazono T, Yamasaki M, Lemonnier FA et al (2009). Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II. Int Immunopharmacol 9: 1183-1188.
38. Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L (2008). PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Res 2008: 295784.
39. Marklund N, Hillered L (2011). Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br J Pharmacol 164: 1207-1229.
40. McTigue DM, Tripathi R, Wei P, Lash AT (2007). The PPAR gamma agonist pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Experimental neurology 205: 396-406.
41. Meredith PA, Murray LS, McMurray JJ (2004). A putative placebo comparison of the SCOPE and LIFE trials. J Renin Angiotensin Aldosterone Syst 5: 59-63.
42. Nishimura Y, Ito T, Hoe K, Saavedra JM (2000). Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 871: 29-38.
43. O'Connor WT, Smyth A, Gilchrist MD (2011). Animal models of traumatic brain injury: a critical evaluation. Pharmacol Ther 130: 106-113.
44. Occleston NL, Laverty HG, O'Kane S, Ferguson MW (2008). Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed 19: 1047-1063.
45. Omura-Matsuoka E, Yagita Y, Sasaki T, Terasaki Y, Oyama N, Sugiyama Y et al (2009). Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. Hypertens Res 32: 548-553.
46. Ozacmak VH, Sayan H, Cetin A, Akyildiz-Igdem A (2007). AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem Res 32: 1314-1321.
47. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM (2012). Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferatoractivated receptor-gamma activation in human monocytes. J Hypertens 30: 87-96.
48. Paul M, Poyan Mehr A, Kreutz R (2006). Physiology of local reninangiotensin systems. Physiol Rev 86: 747-803.
49. Poon IO (2008). Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 28: 366-375.
50. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391: 79-82.
51. Robbins ME, Zhao W, Garcia-Espinosa MA, Diz DI (2010). Reninangiotensin system blockers and modulation of radiationinduced brain injury. Curr Drug Targets 11: 1413-1422.
52. Rodriguez-Pallares J, Rey P, Parga JA, Munoz A, Guerra MJ, Labandeira-Garcia JL (2008). Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPHderived ROS. Neurobiol Dis 31: 58-73.
53. Rosenkranz S (2004). TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63: 423-432.
54. Rotman N, Wahli W (2010). PPAR modulation of kinase-linked receptor signaling in physiology and disease. Physiology (Bethesda) 25: 176-185.
55. Saavedra JM (1992). Brain and pituitary angiotensin. Endocr Rev 13: 329-380.
56. Saavedra JM, Sanchez-Lemus E, Benicky J (2011). Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. Psychoneuroendocrinology 36: 1-18.
57. Santos CC, Zhang H, Liu M, Slutsky AS (2005). Bench-to-bedside review: biotrauma and modulation of the innate immune response. Crit Care 9: 280-286.
58. Savoia C, Schiffrin EL (2007). Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112: 375-384.
59. Sookplung P, Siriussawakul A, Malakouti A, Sharma D, Wang J, Souter MJ et al (2011). Vasopressor use and effect on blood pressure after severe adult traumatic brain injury. Neurocrit Care 15: 46-54.
60. Stenman E, Edvinsson L (2004). Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 35: 970-974.
61. Sugawara A, Uruno A, Matsuda K, Funato T, Saito-Hakoda A, Kudo M et al (2011). Effects of PPARgamma agonists against vascular and renal dysfunction. Curr Mol Pharmacol.
62. Sugawara T, Kinouchi H, Oda M, Shoji H, Omae T, Mizoi K (2005). Candesartan reduces superoxide production after global cerebral ischemia. Neuroreport 16: 325-328.
63. Sun Y, Zhang JQ, Zhang J, Ramires FJ (1998). Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 30: 1559-1569.
64. Susarla BT, Laing ED, Yu P, Katagiri Y, Geller HM, Symes AJ (2011). Smad proteins differentially regulate transforming growth factor-b mediated induction of chondrotin sulfate proteoglycans. J Neurochem 119: 868-878.
65. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME et al (2002). Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11: 21-30.
66. Thone-Reineke C, Steckelings UM, Unger T (2006). Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 24: S115-121.
67. Timaru-Kast R, Wyschkon S, Luh C, Schaible EV, Lehmann F, Merk P et al (2012). Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma*. Crit Care Med 40: 935-944.
68. Tsutsumi K, Saavedra JM (1991). Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 261: R209-216.
69. Van Mieghem W, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F et al (2010). Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend. Acta Clin Belg 65: 107-114.
70. Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C, Baud O (2011). Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res 69: 51-55.
71. Vivien D, Ali C (2006). Transforming growth factor-beta signalling in brain disorders. Cytokine Growth Factor Rev 17: 121-128.
72. Wang Y, Moges H, Bharucha Y, Symes A (2007). Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp Neurol 203: 168-184.
73. Xiao J, Leung JC, Chan LY, Tang SC, Lai KN (2009). Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clin Immunol 132: 266-276.
74. Yamakawa H, Jezova M, Ando H, Saavedra JM (2003). Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 23: 371-380.
75. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R (2008). PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244: 164-172.
76. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP (2001). Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38: 1207-1215.
77. Zanchetti A, Elmfeldt D (2006). Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Press 15: 71-79.
78. Zhao SM, Shen LH, Li HW, Wang L, Chen H, Wang YL et al (2008). Down-regulation of the expression of angiotensin II type 1 receptor in neonatal rat cardiac fibroblast by activation of PPARgamma signal pathway. Chin J Physiol 51: 357-362.
79. Zhou J, Ando H, Macova M, Dou J, Saavedra JM (2005). Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 25: 878-886.
80. Zhou J, Pavel J, Macova M, Yu ZX, Imboden H, Ge L et al (2006). AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 37: 1271-1276.
81. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al (2006). Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552: 112-122.
82. Zuhayra M, Zhao Y, von Forstner C, Henze E, Gohlke P, Culman J et al (2011). Activation of cerebral peroxisome proliferatoractivated receptors gamma (PPARgamma) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat. Neuropathol Appl Neurobiol 37: 738-752.